Study to assess the effect of AZD4831 on the pharmacokinetics (drug behavior in the body) of Midazolam

Exclusion Criteria

• - History of any clinically significant disease or disorder.
• - History or presence of gastrointestinal, hepatic or renal disease, or any other condition
• known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• - A positive Corona Virus Disease 2019 test at Screening or admission to the Clinical Unit on Day -1.
• - Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis
• results.
• - Any clinically significant abnormal findings in vital signs.
• - clinically significant abnormalities on 12-lead electrocardiogram.
• - Any positive result at the Screening Visit for Hepatitis B surface antigen, hepatitis C virus antibody, and human immunodeficiency virus antibody.
• - Known or suspected history of drug abuse in the last 2 years.
• - Current smokers or those who have smoked or used nicotine products within the 3 months prior to the Screening Visit.
• - Known or suspected history of alcohol or drug abuse.
• - Use of any prescribed or non-prescribed medication.
• - Subjects with acute pulmonary insufficiency, marked neuromuscular respiratory
• weakness, obsessional states, phobic states, sleep apnoea syndrome, or unstable
• myasthenia gravis.
• - History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigatoror history of hypersensitivity to drugs with a similar chemical structure or class to AZD4831 or midazolam.
• - History or ongoing allergy/hypersensitivity to drugs(including but not limited to rash, angioedema, acute urticaria).
• - Subjects who, in the opinion of the Investigator, have any clinically significant skin condition.